Cargando…

Autologous Stem Cell Transplant for AL Amyloidosis

AL amyloidosis is caused by clonal plasma cells that produce immunoglobulin light chains which misfold and get deposited as amyloid fibrils. Therapy directed against the plasma cell clone leads to clinical benefit. Melphalan and corticosteroids have been the mainstay of treatment for a number of yea...

Descripción completa

Detalles Bibliográficos
Autor principal: Roy, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361989/
https://www.ncbi.nlm.nih.gov/pubmed/22675637
http://dx.doi.org/10.1155/2012/238961
_version_ 1782234182712295424
author Roy, Vivek
author_facet Roy, Vivek
author_sort Roy, Vivek
collection PubMed
description AL amyloidosis is caused by clonal plasma cells that produce immunoglobulin light chains which misfold and get deposited as amyloid fibrils. Therapy directed against the plasma cell clone leads to clinical benefit. Melphalan and corticosteroids have been the mainstay of treatment for a number of years and the recent availability of other effective agents (IMiDs and proteasome inhibitors) has increased treatment options. Autologous stem cell transplant (ASCT) has been used in the treatment of AL amyloidosis for many years. It is associated with high rates of hematologic response and improvement in organ function. However, transplant carries considerable risks. Careful patient selection is important to minimize transplant related morbidity and mortality and ensure optimal patient outcomes. As newer more affective therapies become available the role and timing of ASCT in the overall treatment strategy of AL amyloidosis will need to be continually reassessed.
format Online
Article
Text
id pubmed-3361989
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33619892012-06-06 Autologous Stem Cell Transplant for AL Amyloidosis Roy, Vivek Bone Marrow Res Review Article AL amyloidosis is caused by clonal plasma cells that produce immunoglobulin light chains which misfold and get deposited as amyloid fibrils. Therapy directed against the plasma cell clone leads to clinical benefit. Melphalan and corticosteroids have been the mainstay of treatment for a number of years and the recent availability of other effective agents (IMiDs and proteasome inhibitors) has increased treatment options. Autologous stem cell transplant (ASCT) has been used in the treatment of AL amyloidosis for many years. It is associated with high rates of hematologic response and improvement in organ function. However, transplant carries considerable risks. Careful patient selection is important to minimize transplant related morbidity and mortality and ensure optimal patient outcomes. As newer more affective therapies become available the role and timing of ASCT in the overall treatment strategy of AL amyloidosis will need to be continually reassessed. Hindawi Publishing Corporation 2012 2012-05-16 /pmc/articles/PMC3361989/ /pubmed/22675637 http://dx.doi.org/10.1155/2012/238961 Text en Copyright © 2012 Vivek Roy. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Roy, Vivek
Autologous Stem Cell Transplant for AL Amyloidosis
title Autologous Stem Cell Transplant for AL Amyloidosis
title_full Autologous Stem Cell Transplant for AL Amyloidosis
title_fullStr Autologous Stem Cell Transplant for AL Amyloidosis
title_full_unstemmed Autologous Stem Cell Transplant for AL Amyloidosis
title_short Autologous Stem Cell Transplant for AL Amyloidosis
title_sort autologous stem cell transplant for al amyloidosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361989/
https://www.ncbi.nlm.nih.gov/pubmed/22675637
http://dx.doi.org/10.1155/2012/238961
work_keys_str_mv AT royvivek autologousstemcelltransplantforalamyloidosis